Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368798 | 1.00 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL29401786 | 1.00 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL3070048 | 1.00 | CASP3 (0.52) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL5706475 | 0.92 | CASP3 (0.47) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL29401235 | 0.90 | CASP3 (0.46) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL3060107 | 0.90 | CASP3 (0.46) | CASP3KMT2APIN1EPHX2 | |
| SCHEMBL29692811 | 0.89 | CTSB (0.48) | CASP3MDM4TP53MDM2 | |
| SCHEMBL7650015 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL12798422 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1EPHX2MDM4 | |
| SCHEMBL29402434 | 0.88 | CASP3 (0.48) | CASP3KMT2APIN1EPHX2MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-05-29 | — | — | US | disclosed |
| EP-4532480-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | Cambridge Enterprise Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023227757-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | NQO1, SQOR, GSTP1 | CASP3 1822/4885KMT2A 662/4885PIN1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.